期刊文献+

2型糖尿病超重或肥胖患者口服降糖药联合地特胰岛素的临床研究 被引量:18

下载PDF
导出
摘要 目的观察口服降糖药血糖控制不佳的2型糖尿病(T2DM)超重或肥胖患者加用地特胰岛素治疗后对血糖及体质量的影响。方法 60例使用口服降糖药血糖控制不佳的T2DM超重或肥胖患者,按随机数字表法分为睡前加用甘精胰岛素组(对照组)和地特胰岛素组(治疗组),每组30例,治疗12周,记录治疗前、后两组患者血糖(FBG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)、胰岛素用量、低血糖事件和体质量的变化。结果治疗12周后,两组患者FBG、HbA1c均较治疗前明显下降,但组间比较差异无统计学意义(P>0.05);两组胰岛素用量相当,低血糖事件发生率相同,均为6.6%,差异无统计学意义(P>0.05);治疗组体质量增加明显低于对照组,差异有统计学意义(P<0.01)。结论口服降糖药血糖控制不佳的T2DM超重或肥胖患者加用地特胰岛素可有效控制血糖,低血糖风险小,且体质量增加少、减少体质量增加的幅度与基线时的BMI呈负相关。
作者 吴军
出处 《重庆医学》 CAS CSCD 北大核心 2014年第24期3236-3238,共3页 Chongqing medicine
  • 相关文献

参考文献14

二级参考文献37

  • 1陆菊明.地特胰岛素的临床实践:PREDICTIVE研究结果分析[J].中华糖尿病杂志,2010,2(1). 被引量:5
  • 2杨坤,郭昆全.胰岛素泵快速控制新诊断2型糖尿病患者高血糖状态对胰岛β细胞功能的影响[J].中国糖尿病杂志,2006,14(6):446-447. 被引量:12
  • 3Heise T,Pieber T R.Towards peakless,reproducible and long-acting insulins.An assessment of the basal analogues based on isoglycaemic clamp studies.Diabetes Obes Metab,2007,9:648-659.
  • 4Russell-Jones D.Insulin detemir:improving the predictability of glycaemic control.Int J Obes Relat Metab Disord,2004,28 Suppl 2:S29-S34.
  • 5Lauritzen T,Faber O K,Binder C.Variation in 125I-insulin absorption and blood glucose concentration.Diabetologia,1979,17:291-295.
  • 6Home P,Kurtzhals P.Insulin detemir:from concept to clinical experience.Expert Opin Pharmacother,2006,7:325-343.
  • 7Heise T,Nosek L,R?nn B B,et al.Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.Diabetes,2004,53:1614-1620.
  • 8Klein O,Lynge J,Endahl L,et al.Albumin-bound basal insulin analogues (insulin detemir and NN344):comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Diabetes Obes Metab,2007,9:290-299.
  • 9Danne T,Datz N,Endahl L,et al.Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes:results from a randomized,double-blind,controlled trial.Pediatr Diabetes,2008,9:554-560.
  • 10Philis-Tsimikas A.An update on the use of insulin detemir,with a focus on type 2 diabetes (drug evaluation update).Expert Opin Pharmacother,2008,9:2181-2195.

共引文献70

同被引文献149

  • 1李玉秀.手术减肥在肥胖2型糖尿病治疗中的作用[J].中国医学科学院学报,2010,32(1):13-15. 被引量:5
  • 2熊同学,杨衍聚,陶永霞,曾宪进,李晓梅,汪胤.综合疗法治疗单纯性肥胖疗效观察[J].针灸临床杂志,2010,26(3):21-23. 被引量:8
  • 3陈秀林.地特胰岛素联合格列美脲对肥胖2型糖尿病患者胰岛素抵抗的影响[J].实用老年医学,2013,27(1):85-87. 被引量:6
  • 4王淑平,赵秀云.地特胰岛素联合阿卡波糖治疗血糖控制不佳的2型糖尿病患者的疗效[J].中国老年学杂志,2014,34(1):243-244. 被引量:9
  • 5Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis : sequelae of insulin-resistant adipose tissue[J]. Circ Res, 2005,96( 10 ): 1042-1052.
  • 6Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008[J]. JAMA, 2010, 303 ( 3 ): 235-241.
  • 7Chan RS, Woo J. Prevention and overweight and obesity : how effective is the current public health approach[J]. Int J Environ lkes Public Health, 2010, 7 ( 3 ) : 765-783.
  • 8Schauer P R, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 3 - year outcomeslJ]. N Eng J Med, 2014, 370 ( 21 ) : 20)2-2013.
  • 9Meneghini LF,Rosenberg KH,Koenen C,et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the predictive 303 stud- y. Diabetes Obes Metab, 2007,3 .. 418-27.
  • 10Rosenstock J, Daves M, Larsen J, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia,2008, 3:408-416.

引证文献18

二级引证文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部